{"id":"combination-of-dmards","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DMARD combinations typically include agents such as methotrexate, sulfasalazine, and hydroxychloroquine, or biologic DMARDs targeting specific immune pathways (TNF inhibitors, IL-6 inhibitors, JAK inhibitors). When used together, they provide complementary immunosuppressive effects that reduce joint inflammation, prevent bone and cartilage damage, and improve clinical outcomes more effectively than monotherapy.","oneSentence":"A combination of disease-modifying antirheumatic drugs (DMARDs) that work synergistically to suppress immune-mediated inflammation and slow progression of rheumatic disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:44.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other inflammatory arthropathies"}]},"trialDetails":[{"nctId":"NCT07484113","phase":"PHASE1","title":"IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-05","conditions":"cGVHD","enrollment":10},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT06945666","phase":"PHASE4","title":"A Study of Iguratimod in Combination With Tofacitinib in RA Patients","status":"NOT_YET_RECRUITING","sponsor":"Jie Chang","startDate":"2025-08-01","conditions":"Rheumatoid Arthritis (RA","enrollment":200},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT04928586","phase":"PHASE4","title":"Immunosuppressant Combined With Pirfenidone in CTD-ILD","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2019-08-16","conditions":"Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease","enrollment":200},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT03886038","phase":"PHASE4","title":"Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)","status":"COMPLETED","sponsor":"Region Skane","startDate":"2019-03-15","conditions":"Rheumatoid Arthritis, Healthy Controls","enrollment":142},{"nctId":"NCT05671627","phase":"","title":"Cortisol Circadian Rhythm in Patients With RA","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2022-02-02","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT00783536","phase":"PHASE4","title":"A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT01881308","phase":"PHASE4","title":"Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-06-17","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT04454034","phase":"","title":"Arthroscopic Synovectomy Combined With DMARDs in the Treatment of Refractory Elbow Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2019-08-01","conditions":"Rheumatoid Arthritis of Ankle","enrollment":25},{"nctId":"NCT04927000","phase":"PHASE4","title":"The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-05-31","conditions":"Rheumatoid Arthritis","enrollment":170},{"nctId":"NCT03964649","phase":"","title":"Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-01","conditions":"Arthritis, Rheumatoid","enrollment":7308},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03682705","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":242},{"nctId":"NCT02799472","phase":"PHASE2","title":"Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-15","conditions":"Arthritis, Rheumatoid","enrollment":39},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT03264703","phase":"","title":"Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2017-09-11","conditions":"Arthritis, Rheumatoid","enrollment":212},{"nctId":"NCT02644499","phase":"PHASE4","title":"Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":186},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT02648035","phase":"","title":"EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-22","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT01521923","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":359},{"nctId":"NCT01519791","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":880},{"nctId":"NCT01787149","phase":"PHASE3","title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Mycenax Biotech Inc.","startDate":"2013-09","conditions":"Combination With DMARDs","enrollment":98},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT00951275","phase":"PHASE3","title":"A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Rheumatoid Arthritis","enrollment":105},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00996606","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":58},{"nctId":"NCT00443651","phase":"PHASE3","title":"A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-01","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT01489384","phase":"","title":"Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)","status":"UNKNOWN","sponsor":"Pope Research Corporation","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":125},{"nctId":"NCT01759030","phase":"PHASE3","title":"Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":181},{"nctId":"NCT01791205","phase":"","title":"ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":304},{"nctId":"NCT02011334","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07","conditions":"Rheumatoid Arthritis","enrollment":285},{"nctId":"NCT01878318","phase":"PHASE4","title":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT01194414","phase":"PHASE3","title":"A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":1262},{"nctId":"NCT02643823","phase":"PHASE1","title":"Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT00848354","phase":"PHASE4","title":"Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":429},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT01214733","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT01232569","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":656},{"nctId":"NCT01106079","phase":"PHASE3","title":"TIght COntrol of Psoriatic Arthritis","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2008-05","conditions":"Psoriatic Arthritis","enrollment":206},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01254331","phase":"PHASE3","title":"An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":51},{"nctId":"NCT01251120","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT01235507","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":71},{"nctId":"NCT00766402","phase":"PHASE4","title":"An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-10","conditions":"Spondylitis, Ankylosing, Pain","enrollment":8},{"nctId":"NCT01089023","phase":"PHASE4","title":"A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":95},{"nctId":"NCT01353859","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT01915537","phase":"NA","title":"Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients","status":"UNKNOWN","sponsor":"Zhang, Xiao, M.D.","startDate":"2013-08","conditions":"Rheumatoid Arthritis（RA）","enrollment":170},{"nctId":"NCT01547091","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Alliancells Bioscience Corporation Limited","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT00078793","phase":"","title":"Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-06","conditions":"Juvenile Rheumatoid Arthritis","enrollment":600},{"nctId":"NCT01040195","phase":"PHASE3","title":"Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2009-06","conditions":"Seronegative Spondyloarthropathies","enrollment":33},{"nctId":"NCT01299545","phase":"","title":"Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":123},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT01292616","phase":"","title":"Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2011-10","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT00117091","phase":"PHASE3","title":"Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MTX: Trexan or Methotrexate, SSZ: Salazopyrin, HCQ: Oxiklorin"],"phase":"phase_3","status":"active","brandName":"Combination of DMARDs","genericName":"Combination of DMARDs","companyName":"Helsinki University Central Hospital","companyId":"helsinki-university-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination of disease-modifying antirheumatic drugs (DMARDs) that work synergistically to suppress immune-mediated inflammation and slow progression of rheumatic disease. Used for Rheumatoid arthritis, Other inflammatory arthropathies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}